Auscandoc on Nostr: Association of Semaglutide With #TobaccoUseDisorder in Patients With Type 2 Diabetes: ...
Association of Semaglutide With #TobaccoUseDisorder in Patients With Type 2 Diabetes:
https://www.acpjournals.org/doi/10.7326/M23-2718 “#Semaglutide was associated with lower risks for TUD-related health care measures in patients with comorbid #T2DM and #TUD compared with other antidiabetes medications including other #GLP1Ras, primarily within 30 days of prescription. These findings suggest the need for clinical trials to evaluate semaglutide’s potential for TUD treatment.”
Published at
2024-07-30 15:06:26Event JSON
{
"id": "4d7c6adcac2c2646b6ace74a832f48b2798db66e525335eb7955c53fe92147be",
"pubkey": "5f1623d9b62000b1b0d49dd3b39025aee932784b44e20ab52da2a28298ce9871",
"created_at": 1722351986,
"kind": 1,
"tags": [
[
"t",
"tobaccousedisorder"
],
[
"t",
"semaglutide"
],
[
"t",
"t2dm"
],
[
"t",
"tud"
],
[
"t",
"glp1ras"
],
[
"proxy",
"https://med-mastodon.com/users/auscandoc/statuses/112876059757904927",
"activitypub"
]
],
"content": "Association of Semaglutide With #TobaccoUseDisorder in Patients With Type 2 Diabetes: https://www.acpjournals.org/doi/10.7326/M23-2718 “#Semaglutide was associated with lower risks for TUD-related health care measures in patients with comorbid #T2DM and #TUD compared with other antidiabetes medications including other #GLP1Ras, primarily within 30 days of prescription. These findings suggest the need for clinical trials to evaluate semaglutide’s potential for TUD treatment.”",
"sig": "59c2a088c41aeb1be41aa6bb0645ab28f732880619b58186c2f584d2919d11bd11ed0e1b69688411c13c373f4411105c66b669f66e092004d51b0f26d0415bdf"
}
